Cardiology drug pipeline

Cardiovascular disease therapeutics — hypertension, heart failure, atrial fibrillation, dyslipidaemia, thrombosis.

Recent approvals (last 30 days)

No approvals in this window.

Upcoming PDUFA dates (next 6 months)

No upcoming decisions in this window.

Top sponsors

1. · 155 drugs
2. Novartis · 34 drugs
3. Sanofi · 32 drugs
4. Organon and Co · 28 drugs
5. Bayer · 27 drugs
6. Assistance Publique - Hôpitaux de Paris · 27 drugs
7. Pfizer · 25 drugs
8. Boryung Pharmaceutical Co., Ltd · 23 drugs
9. AstraZeneca · 22 drugs
10. Takeda · 19 drugs

Key drug classes

• HMG-CoA reductase inhibitor (statin) · 45
• Anticoagulant · 41
• ACE inhibitor · 39
• Low-molecular-weight heparin (LMWH) · 37
• Angiotensin II receptor blocker (ARB) · 30
• Loop diuretic · 25
• Calcium channel blocker · 19
• Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent · 18
• Factor Xa inhibitor · 17
• PCSK9 inhibitor · 17
• Dual antiplatelet agent · 14
• Calcium channel blocker (dihydropyridine) · 13
• Nitrate vasodilator · 13
• Angiotensin II receptor blocker / Calcium channel blocker combination · 12
• Direct Factor Xa inhibitor · 12

Major diseases in this area

• atrial fibrillation
• heart failure
• hypertension

Subscribe

Get cardiology approvals + PDUFA dates in your RSS reader:

• Cardiology RSS feed · Atom · JSON

Other therapeutic areas